In short
UBT251 is an investigational medicine being studied for type 2 diabetes. A Phase 2 trial is currently authorised to compare different doses of UBT251 against semaglutide (Ozempic) in 300 people with type 2 diabetes. The trial will measure how well UBT251 lowers blood sugar over 12 weeks of maintenance treatment.
UBT251 is an investigational medicine being studied for the treatment of type 2 diabetes. The full name of the product used in the trial is UBT251 A 10169. No marketing authorisation for UBT251 is mentioned in the available registry data, which means it is still being researched and is not yet approved as a medicine.
Key points
- UBT251 is an investigational medicine for type 2 diabetes.
- The authorised trial is a Phase 2 study with 300 participants.
- UBT251 is given as a subcutaneous injection once weekly.
- The trial compares UBT251 with semaglutide (Ozempic) and placebo.
- The main measure is the change in HbA1c from baseline to 12 weeks on a maintenance dose.
- Participants are people whose type 2 diabetes is not well controlled on metformin, with or without an SGLT2 inhibitor.
What is UBT251?
UBT251 is an investigational substance studied in the therapeutic area of type 2 diabetes. The trial record lists the intervention as a drug product called UBT251 A 10169, given by subcutaneous injection. The registry does not provide a chemical class or mechanism-of-action description for UBT251. It is not described as an authorised medicine in the available data.
How does UBT251 work?
The available registry record does not explain the mechanism of action of UBT251. The trial is designed to characterise the dose-response relationship of UBT251 for changing HbA1c, which suggests the medicine is expected to lower blood sugar, but the biological target or pathway is not stated in the data.
Which conditions is UBT251 being studied for?
- Type 2 diabetes (T2D) — a long-term condition in which the body does not use insulin properly, leading to high blood sugar. The trial focuses on people whose type 2 diabetes is inadequately controlled with metformin, with or without an SGLT2 inhibitor.
How is UBT251 given?
UBT251 is given as a subcutaneous injection, which means it is injected under the skin. The trial brief summary states that UBT251 is administered once weekly. The dose strength is not reported in the registry record.
What do the clinical trials show?
One clinical trial of UBT251 is listed in the registry. It is a Phase 2 interventional study with 300 participants, currently authorised. The trial is designed to demonstrate and characterise the dose-response relationship of once-weekly subcutaneous UBT251 for change in HbA1c from baseline to 12 weeks on a given maintenance dose.
The main measure, or primary outcome, is the change in HbA1c from baseline at week 0 to 12 weeks on a given maintenance dose, assessed at weeks 16, 28 and 40. HbA1c is a blood test that shows average blood sugar levels over the previous two to three months. The trial compares UBT251 with semaglutide, sold as Ozempic, and with placebo injections. Semaglutide and placebo are comparison arms, not the studied substance.
The people who can take part are patients with type 2 diabetes whose blood sugar is not adequately controlled with metformin, with or without an SGLT2 inhibitor. The trial status is authorised, meaning the study has received approval and may proceed.
What side effects are known?
The registry record for this trial does not provide information on side effects of UBT251. No supplementary sources describing side effects were provided.